interleukin-8 has been researched along with doxofylline* in 1 studies
1 other study(ies) available for interleukin-8 and doxofylline
| Article | Year |
|---|---|
Doxofylline does not increase formoterol-induced cAMP nor MKP-1 expression in ASM cells resulting in lack of anti-inflammatory effect.
The xanthine doxofylline has been examined in clinical trials and shown to have efficacy and greater tolerability than theophylline in asthma and chronic obstructive pulmonary disease. The 'novofylline' doxofylline has demonstrated bronchodilatory and anti-inflammatory actions in in vivo and ex vivo experimental models of respiratory disease. However, there are limited studies in vitro. We address this herein and examine whether doxofylline has anti-inflammatory impact on primary cultures of airway smooth muscle (ASM) cells. We conduct a series of investigations comparing and contrasting doxofylline with the archetypal xanthine, theophylline, and the specific phosphodiesterase (PDE) 4 inhibitor, cilomilast. We confirm that the xanthine drugs do not have action as PDE inhibitors in ASM cells. Unlike cilomilast, doxofylline (and theophylline) do not increase cAMP production in ASM cells induced by long-acting β Topics: Anti-Inflammatory Agents; Bronchi; Bronchodilator Agents; Cells, Cultured; Cyclic AMP; Cyclohexanecarboxylic Acids; Dual Specificity Phosphatase 1; Formoterol Fumarate; Humans; Inflammation; Interleukin-8; Myocytes, Smooth Muscle; Nitriles; Phosphodiesterase Inhibitors; Theophylline; Tumor Necrosis Factor-alpha | 2017 |